NFKB1 and Miyoshi myopathy: Aside from improvements in therapeutic design, novel drugs are designed to target specific molecular mechanisms involved in MM, especially the nuclear factor kappa B (NF-κB) signaling pathway [8,9,10], which is described in the following context.